The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model

Eur J Cancer. 2021 Nov:157:518-519. doi: 10.1016/j.ejca.2021.08.042. Epub 2021 Sep 24.

Authors

Alexander M M Eggermont¹, Domenico Bellomo², Jvalini Dwarkasing², Lisette Meerstein-Kessel², Alexander Meves³

Affiliations

¹ Princess Máxima Center, Utrecht, the Netherlands; University Medical Center Utrecht, Utrecht, the Netherlands.
² SkylineDx B.V., Rotterdam, the Netherlands.
³ Mayo Clinic, Rochester, MN, USA. Electronic address: meves.alexander@mayo.edu.

PMID: 34565669
DOI: 10.1016/j.ejca.2021.08.042

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Gene Expression
Humans
Melanoma* / genetics
Recurrence
Skin Neoplasms* / genetics